Varenicline and Depression: What the Evidence Shows

Last reviewed: November 15, 2026Next review due: November 2027

Key takeaways

The EAGLES trial randomized 8,144 smokers to varenicline, bupropion, a nicotine patch or placebo. It did not show a significant increase in serious neuropsychiatric events from varenicline or bupropion. Health Canada's monograph still lists post-marketing reports of mood and behaviour changes, so people should tell a clinician about any change.

Mood is the question most people ask before taking varenicline, and it comes from reports that began after the medicine reached the market. A large trial was designed to answer it, and Health Canada’s monograph summarizes the result. This page reads both sources and reports their numbers, so you can talk to your prescriber with the figures in hand.

What were the original safety concerns?

Health Canada’s product monograph says there have been post-marketing reports of serious neuropsychiatric symptoms in patients treated with varenicline. It lists anxiety, psychosis, mood swings, depressed mood, agitation, aggression, hostility, changes in behaviour or thinking, suicidal ideation, suicidal behaviour and suicide, and worsening of an existing psychiatric disorder. It adds that not all patients had stopped smoking when symptoms began, and that not all had known psychiatric illness.

Reports like these cannot show cause. The people who take a quit-smoking medicine are also going through nicotine withdrawal, and the monograph recommends that clinicians be aware that serious neuropsychiatric symptoms can emerge in people trying to quit, with or without treatment.

How was the EAGLES trial designed?

The 2016 EAGLES trial was randomized, double-blind and placebo-controlled, with a nicotine patch as a second comparison. It enrolled 8,144 smokers at 140 centres in 16 countries. People received varenicline, bupropion, a 21 mg nicotine patch with taper, or placebo for 12 weeks, then 12 more weeks of follow-up without treatment. Everyone received brief quitting counselling.

About half had a psychiatric disorder, so the trial split them into a psychiatric cohort (4,116 people) and a non-psychiatric cohort (4,028). The monograph says subjects were aged 18 to 75, smoked 10 or more cigarettes a day and were judged clinically stable, and that current substance abuse, dementia, impulse control and dissociative disorders were excluded. The primary safety endpoint was a composite of moderate and severe neuropsychiatric events.

What did it find about mood and behaviour?

In people without a psychiatric disorder, the composite event rate was 1.3% with varenicline, 2.2% with bupropion, 2.5% with the nicotine patch and 2.4% with placebo.

In people with a psychiatric disorder, event rates were higher in every group: 6.5% with varenicline, 6.7% with bupropion, 5.2% with the patch and 4.9% with placebo. The monograph points out that the rate for each active medicine was above placebo in this cohort, but in neither cohort was varenicline or bupropion associated with a significantly increased risk compared with placebo. The authors concluded that the study did not show a significant increase in neuropsychiatric adverse events attributable to varenicline or bupropion.

The most common side effect was not psychiatric. Nausea was reported by 25% of the people taking varenicline.

Does it hold for depression, anxiety and psychosis?

A 2019 analysis looked at the 4,092 people with a primary psychotic (390), anxiety (792) or mood (2,910) disorder. Event rates ranged from 5.1% to 6.3% in psychotic disorders, 4.6% to 8.0% in anxiety disorders and 4.6% to 6.8% in mood disorders across the treatments. Neither varenicline nor bupropion was associated with significantly more events than the patch or placebo in any group. The authors concluded that varenicline, bupropion and the patch were well tolerated and effective in adults with psychotic, anxiety and mood disorders.

Did the medicines work?

Yes, and by different amounts. Varenicline had higher quit rates than placebo (odds ratio 3.61), the nicotine patch (1.68) and bupropion (1.75) over weeks 9 to 12. For a side-by-side look at the three options, see our comparison of varenicline, bupropion and nicotine replacement.

What the evidence does not settle

The trial ran for 12 weeks of treatment and 12 weeks of follow-up, and the drug makers funded it. It enrolled adults who were stable, so it does not describe people with unstable symptoms, teenagers or people with excluded conditions. A trial cannot rule out a rare reaction in one person.

If you have a history of depression or anxiety, the practical step is to tell your prescriber before starting. Our pages on quitting with a mental illness and on smoking and depression explain how services support people in that situation. For all options, including nicotine replacement and cytisine, see quit smoking medications in Canada.

What we could not confirm

  • Whether Health Canada has revised the monograph wording since the version we read.
  • The risk for an individual person, which the trial results cannot predict.
  • Safety in people under 18, which the trial did not cover.
  • Results for generic varenicline products specifically.

This page is general information, not medical advice. A doctor, nurse practitioner or pharmacist can review your own history.

Health information is general and educational. It does not replace advice from a doctor, pharmacist or nurse. Read the full disclaimer.

Frequently asked questions

Does varenicline cause depression?

The EAGLES trial did not show a significant increase in moderate or severe neuropsychiatric events from varenicline compared with placebo or the nicotine patch. Health Canada's monograph still lists post-marketing reports of depressed mood and suicidal thoughts, so any change in mood is worth reporting.

Was the trial done in people with mental health conditions?

Yes. About half of the 8,144 participants had a psychiatric disorder, most often a mood disorder. The monograph says they were judged clinically stable and that some conditions, such as current substance abuse, were excluded.

Can quitting smoking itself affect mood?

The monograph says clinicians should be aware that serious neuropsychiatric symptoms can emerge in people attempting to quit smoking, with or without treatment.

What should I do if my mood changes while I am taking it?

Tell your prescriber or pharmacist. The monograph advises clinicians to watch for such symptoms, and the post-marketing reports include anxiety, depressed mood, agitation and suicidal thoughts.

Sources

  1. EAGLES trial: neuropsychiatric safety and efficacy (2016) — PubMed (US National Library of Medicine). Accessed November 15, 2026.
  2. EAGLES trial: psychotic, anxiety and mood disorders (2019) — PubMed Central (US National Library of Medicine). Accessed November 15, 2026.
  3. Varenicline product monograph — Health Canada (Drug Product Database). Accessed November 15, 2026.
Disclaimer: the information on this site is for general reference only. It is not medical, legal or financial advice. Laws, rates and programs change, so check the official source before you rely on any detail.